1.1500 -0.04 (-3.36%)
After hours: 4:01PM EDT
|Mr. Jeffrey Alan Wolf||Founder, Chairman, CEO & Pres||808.23k||N/A||1963|
|Mr. William L. Ostrander||VP of Fin., Controller & Sec.||230.62k||N/A||1968|
|Dr. Jeff T. Hutchins||Chief Scientific Officer & COO||446.39k||N/A||1959|
|Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.||Chief Medical Advisor and Member of Scientific & Clinical Advisory Board||N/A||N/A||N/A|
|Colonel George E. Peoples Jr., F.A.C.S., M.D., FACS||Chief Medical Advisor||N/A||N/A||N/A|
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.